Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Elranatamab Shows Activity, Safety as Compassionate Use in R/R Multiple Myeloma

August 13th 2024

Mohamad Mohty, MD, PhD, discusses real-world data for elranatamab in relapsed/refractory multiple myeloma in the French compassionate use program.

Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma

August 12th 2024

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

August 12th 2024

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Isatuximab Plus VRd Improves PFS in Transplant-Eligible, Newly Diagnosed Myeloma

August 8th 2024

Isatuximab plus VRd induction improved progression-free survival in transplant-eligible, newly diagnosed multiple myeloma.

Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

August 7th 2024

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

August 6th 2024

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Dr Battiwalla on Addressing Unmet Needs in Multiple Myeloma

August 5th 2024

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma

August 2nd 2024

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

FDA Approves Subcutaneous Daratumumab Plus VRd in Multiple Myeloma

July 30th 2024

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

Dr Neparidze on the Implications of Early Data for Belantamab Mafodotin Plus Elotuzumab in R/R Myeloma

July 30th 2024

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma

July 25th 2024

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

July 24th 2024

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Dr Siegel on the Need for Durable Remissions in Patients With Multiple Myeloma

July 23rd 2024

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

July 19th 2024

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

July 19th 2024

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

July 18th 2024

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

July 18th 2024

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

Dr Biran on the IMROZ Trial in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 17th 2024

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

July 17th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.